<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576235</url>
  </required_header>
  <id_info>
    <org_study_id>VM_PG102P</org_study_id>
    <nct_id>NCT03576235</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients</brief_title>
  <acronym>SNUG</acronym>
  <official_title>Safety and Efficacy of PG102P for the coNtrol of prUritus in Patients underGoing Hemodialysis (SNUG Trial): Study Protocol for a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study (SNUG trial), the investigators aim to investigate the anti-pruritic effect of
      PG102P in comparison with placebo in 80 patients undergoing HD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled trial in which one group
      will be treated with PG102P (1.5 g/day) and the other with a placebo. It is an
      investigator-initiated clinical trial. A superiority trial is planned to test the hypothesis
      that PG102P is effective in relieving pruritus for patients with ESRD undergoing HD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS change from baseline</measure>
    <time_frame>the change in VAS between visit 2 (week 0) and visits 3, 4, 5, and 6 (weeks 2, 4, 8, 10)</time_frame>
    <description>The primary endpoint is the change in VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum total IgE</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>immunoglobulin E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood Eosinophil count</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>Eosinophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ECP</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>Eosinophil Cationic Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Ca</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>serum Calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum P</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>serum Phosphorus,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum K</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>serum Potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum iPTH</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>intact parathyroid hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire #1 (KDQOL, Kidney Disease and Quality of Life)</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>The KDQOL-SF 1.3 includes 43 kidney disease targeted items as well as 36 items that provide a generic core and a overall health rating items (SF-36). The lowest and highest scores of each items are set at 0 to 100, with higher scores reflecting better quality of life.
Kidney disease targeted (number of items)
Symptoms/Problems (12), Effects of kidney disease (8), Burden of kidney disease (4), Work status (2), Cognitive function (3), Quality of social interaction (3), Sexual function (2), Sleep (4), Social support (2), Dialysis staff encouragement (2), Patient satisfaction rating (1), Overall heath rating (1)
SF-36 (number of items)
Physical functioning (10), Role-physical (4), Bodily pain (2), General health (5), Mental health (5), Role-emotional (3), Social functioning (2), Vitality (4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire #2 (BDI, Beck's Depression Inventory)</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>The Beck Depression Inventory (BDI-II) is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Each answer is scored 0-3 with a maximum score of 63 points, and higher total scores indicate more severe depressive symptoms.
0-13: minimal depression, 14-19: mild depression, 20-28: moderate depression, 29-63: severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-31</measure>
    <time_frame>week 0, week 8</time_frame>
    <description>inflammatory cytokine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Uremic Pruritus</condition>
  <arm_group>
    <arm_group_label>a treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PG102P 1.5 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>a control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG102P</intervention_name>
    <description>Daily dose of 1.5g</description>
    <arm_group_label>a treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily dose of placebo</description>
    <arm_group_label>a control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 19 years

          2. Patients with adequate HD (Kt/V &gt; 1.2)

          3. Maintenance patients undergoing HD with chronic pruritus

          4. Mean visual analog scale (VAS) over 4 of the last 5 days in the 14-day pre-observation
             period

          5. Participants who allowed to continue the anti-pruritic drug treatment at the same
             dosage and administration schedule as used at baseline throughout the study period

          6. Patients who agreed to participate in this trial and had written an informed consent

        Exclusion Criteria:

          1. Intact parathyroid hormone (iPTH) &gt; 1000 pg/mL within 1 month

          2. Serum potassium &gt; 7.0 mg/dL

          3. HIV Ab (+)

          4. Aspartate transaminase (AST) (glutamic oxaloacetic transaminase) or alanine
             transaminase (ALT) (glutamic pyruvic transaminase) &gt; 3 times the upper limit of normal

          5. Scheduled to have kidney transplantation within 3 months

          6. Cancer history with current treatment

          7. Active infection with current treatment

          8. Current itching with dermatologic diseases other than uremic pruritus

          9. Pregnancy, childbearing potential during the study period, or breastfeeding

         10. Allergy or hypersensitivity reaction to PG102P

         11. History of participating another clinical trial within 2 months or planning to
             participate another clinical trial

         12. Not eligible to participate this trial as researchers' decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Soo Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Boramae Medical Center, Seoul, Republic of Korea.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Chun Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Uremic pruritus</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

